BIOMARKERS FOR DIAGNOSIS OF DIFFERENTIATED THYROID CANCER

摘要

A method of diagnosing differentiated thyroid cancer in a subject is described. The method comprises obtaining a thyroid tissue sample from the subject; determining, in the sample, a level of each member of a plurality of biomarkers in the sample, and comparing the levels determined against a reference to determine if the levels indicate differentiated thyroid cancer. The plurality of biomarkers may be a panel comprising: (a) Galectin-3, P16 and androgen receptor; (b) Galectin-3, P16 and HBME-1; or (c) Cytokeratin 19 and Vascular Endothelial Growth Factor, each of which may be used in conjunction with additional biomarkers.